Clinical Trial Update: A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial assessing continuation of RoActemra/Actemra (tocilizumab) in patients with multicentric Castleman's disease who previously benefited from treatmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castleman Disease
• Multicentric Castleman Disease

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Castleman's Disease | Phase 1 | Status: COMPLETED